Structure Therapeutics Inc. (GPCR) Stock Price & Analysis

Structure Therapeutics Inc. (GPCR) rose 9.21% to USD 41.25 as of June 10, 2026 at 03:34 UTC, according to Nexqual real-time market data.

GPCR last closed at USD 37.77; the session ranged USD 39.11–41.8 on volume of 1,864,997 shares. Market capitalization is $2.93B, with a 52-week range of USD 15.8–94.9 (NGM). Source: Nexqual, June 10, 2026 at 03:34 UTC.

Key Statistics (as of June 10, 2026 at 03:34 UTC)

Technical Analysis (GPCR)

Nexqual's technical model rates GPCR "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:34 UTC.

Analyst Ratings (GPCR)

Wall Street analysts rate GPCR "Strong Buy" based on 16 analysts, with a mean price target of USD 106.47 (range USD 69.5–145), per Nexqual as of June 10, 2026 at 03:34 UTC.

Earnings (GPCR)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:34 UTC.

Financials & Fundamentals (GPCR)

Source: Nexqual, June 10, 2026 at 03:34 UTC.

Financial Health Score (GPCR)

Nexqual rates Structure Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:34 UTC.

Ownership (GPCR)

Source: Nexqual, June 10, 2026 at 03:34 UTC.

Leadership (GPCR)

Structure Therapeutics Inc. is led by Raymond C. Stevens (age 61), CEO & Director, per Nexqual as of June 10, 2026 at 03:34 UTC.

Major Backers & Investors (GPCR)

Notable institutional backers of Structure Therapeutics Inc. include FMR, LLC, Wellington Management, Avoro Capital Advisors LLC, according to Nexqual as of June 10, 2026 at 03:34 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:34 UTC.

From Structure Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Through this iterative process, we can accelerate evaluation and optimization of molecules in silico ahead of synthesis and assay and then further optimize them through additional cycles of computation analysis. 30 Table of Contents Structure Therapeutics Integrated Platform As shown above, our collaborations with Schrödinger in our computational and chemistry module enables us to accelerate our lead optimization drug discovery process and reduce development costs.
• Other Proprietary In-House Development Tools for Drug Synthesis and Screening In addition to our robust iterative structure-based drug discovery platform shown above, Basecamp Bio is optimizing proprietary in-house drug discovery tools including DNA-Encoded Library technology and Affinity Mass Spectrometry technology to enable the synthesis and screening of vast numbers of small molecule product candidates at a scale that is not possible to achieve by traditional methods.
• In total, our patent portfolio comprises over 480 patents and patent applications, as of December 31, 2025, filed in various jurisdictions worldwide.
• Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.

Partnerships

• Lhotse Collaboration Agreement with Schrödinger, LLC In October 2020, Lhotse, our wholly-owned subsidiary, entered into a collaboration agreement with Schrödinger (the "Lhotse-Schrödinger Agreement") to discover and develop novel, orally bioavailable, small molecule inhibitors of LPA1R.
• Aconcagua Collaboration Agreement with Schrödinger In November 2023, Aconcagua, our wholly-owned subsidiary, entered into a collaboration agreement (the "Aconcagua-Schrödinger Agreement") with Schrödinger to discover and develop novel, small molecule modulators of a specific target.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:34 UTC. This page is informational and not investment advice.